GlassScriptPhysician profile
Rohan U Mehta
NPI 1104356955
$1,583.46
in general payments reported to CMS, 2019-2025
32 companies · $697 in 2025
The $697 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108 · 2020: $22.71 · 2021: $82.03 · 2022: $107 · 2023: $139 · 2024: $429 · 2025: $697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,141 · Education: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,141.27 |
| Education | $122.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $153.85 | 2021-2025 | |
| Incyte Corporation | $124.99 | 2024 | Jakafi |
| Novartis Pharmaceuticals Corporation | $122.07 | 2025 | |
| Genmab U.S., INC. | $110.18 | 2024 | Epkinly |
| Lilly USA, LLC | $107.01 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $99.95 | 2023 | |
| Daiichi Sankyo INC. | $94.48 | 2024-2025 | Enhertu, Vanflyta |
| Pharmacosmos Therapeutics INC. | $79.19 | 2024 | Cosela |
| Biosense Webster, INC. | $70.76 | 2019 | |
| Glaxosmithkline, LLC. | $56.60 | 2025 | Jemperli, Zejula, Ojjaara |
| Merck Sharp & Dohme LLC | $47.28 | 2021-2024 | Keytruda, Welireg |
| Pfizer INC. | $41.97 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $40.99 | 2019-2020 | |
| Adaptive Biotechnologies Corporation | $38.07 | 2024-2025 | Clonoseq |
| Eisai INC. | $34.53 | 2025 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $32.98 | 2025 | |
| Janssen Biotech, INC. | $32.17 | 2021-2025 | Rybrevant |
| Heartflow, INC. | $23.51 | 2021 | |
| Azurity Pharmaceuticals, INC. | $22.81 | 2025 | Vivimusta, Danziten |
| Almatica Pharma LLC | $22.27 | 2025 | Teriparatide |
| Taiho Oncology, INC. | $22.23 | 2025 | |
| Seagen INC. | $21.71 | 2023 | Tukysa |
| Tonix Medicines, INC. | $21.01 | 2025 | Tonmya |
| Caris Mpi, INC. | $20.82 | 2025 | Mi Cancer Seek |
| Adc Therapeutics America, INC. | $19.99 | 2024 | |
| Sobi, INC | $18.98 | 2025 | |
| Zoll Circulation INC | $18.95 | 2019 | |
| Exelixis INC. | $18.56 | 2024 | Cabometyx |
| Array Biopharma INC | $17.15 | 2025 | Braftovi, Mektovi, Lorbrena |
| Genentech USA, INC. | $17.03 | 2025 | Itovebi |
| Apellis Pharmaceuticals, INC. | $16.90 | 2023 | Empaveli |
| Emd Serono, INC. | $14.47 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohan Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.